---
title: "J.P. Morgan Remains a Buy on WuXi AppTec Co., Ltd. Class H (2359)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280747986.md"
description: "J.P. Morgan analyst Yang Huang has maintained a Buy rating on WuXi AppTec Co., Ltd. Class H (2359), setting a price target of HK$150.00. The analyst is ranked #528 out of 12,068 analysts according to TipRanks. The consensus among analysts for WuXi AppTec Co., Ltd. Class H is a Strong Buy, with a price target consensus of HK$146.84."
datetime: "2026-03-27T07:45:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280747986.md)
  - [en](https://longbridge.com/en/news/280747986.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280747986.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280747986.md) | [繁體中文](https://longbridge.com/zh-HK/news/280747986.md)


# J.P. Morgan Remains a Buy on WuXi AppTec Co., Ltd. Class H (2359)

In a report released yesterday, Yang Huang from J.P. Morgan maintained a Buy rating on WuXi AppTec Co., Ltd. Class H, with a price target of HK$150.00.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Huang is ranked #528 out of 12068 analysts.

WuXi AppTec Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of HK$146.84.

### Related Stocks

- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)
- [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/en/quote/159570.CN.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)
- [WUXI APPTEC (02359.HK)](https://longbridge.com/en/quote/02359.HK.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md)
- [WuXi AppTec (603259.CN)](https://longbridge.com/en/quote/603259.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/en/quote/520500.CN.md)

## Related News & Research

- [Seres Group Refines AGM Agenda With Detailed Share Buyback Resolutions](https://longbridge.com/en/news/281431575.md)
- [Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst⢠(bumetanide nasal spray)](https://longbridge.com/en/news/281570860.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)
- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/en/news/281103720.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md)